Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Total Debt (2021 - 2026)

Indivior Pharmaceuticals has reported Total Debt over the past 6 years, most recently at $486.0 million for Q1 2026.

  • For Q1 2026, Total Debt rose 47.72% year-over-year to $486.0 million; the TTM value through Mar 2026 reached $486.0 million, up 47.72%, while the annual FY2025 figure was $319.0 million, 4.2% down from the prior year.
  • Total Debt for Q1 2026 was $486.0 million at Indivior Pharmaceuticals, up from $319.0 million in the prior quarter.
  • Over five years, Total Debt peaked at $486.0 million in Q1 2026 and troughed at $240.0 million in Q4 2022.
  • A 5-year average of $324.4 million and a median of $324.0 million in 2025 define the central range for Total Debt.
  • Biggest five-year swings in Total Debt: decreased 4.2% in 2025 and later soared 47.72% in 2026.
  • Year by year, Total Debt stood at $240.0 million in 2022, then changed by 0.0% to $240.0 million in 2023, then soared by 38.75% to $333.0 million in 2024, then dropped by 4.2% to $319.0 million in 2025, then surged by 52.35% to $486.0 million in 2026.
  • Business Quant data shows Total Debt for INDV at $486.0 million in Q1 2026, $319.0 million in Q4 2025, and $322.0 million in Q3 2025.